Now showing items 21-25 of 25

    • Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma.

      Morris, M R; Gentle, D; Abdulrahman, M; Clarke, Noel W; Brown, Michael D; Kishida, Takeshi; Yao, M; Teh, B T; Latif, Farida; Maher, Eamonn R; et al. (2008-01-29)
      Promoter region hypermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many human cancers. Previously, to identify candidate epigenetically inactivated TSGs in renal cell carcinoma (RCC), we monitored changes in gene expression in four RCC cell lines after treatment with the demethylating agent 5-azacytidine. This enabled us to identify HAI-2/SPINT2 as a novel epigenetically inactivated candidate RCC TSG. To identify further candidate TSGs, we undertook bioinformatic and molecular genetic evaluation of a further 60 genes differentially expressed after demethylation. In addition to HAI-2/SPINT2, four genes (PLAU, CDH1, IGFB3 and MT1G) had previously been shown to undergo promoter methylation in RCC. After bioinformatic prioritisation, expression and/or methylation analysis of RCC cell lines+/-primary tumours was performed for 34 genes. KRT19 and CXCL16 were methylated in RCC cell lines and primary RCC; however, 22 genes were differentially expressed after demethylation but did not show primary tumour-specific methylation (methylated in normal tissue (n=1); methylated only in RCC cell lines (n=9) and not methylated in RCC cell lines (n=12)). Re-expression of CXCL16 reduced growth of an RCC cell line in vitro. In a summary, a functional epigenomic analysis of four RCC cell lines using microarrays representing 11 000 human genes yielded both known and novel candidate TSGs epigenetically inactivated in RCC, suggesting that this is valid strategy for the identification of novel TSGs and biomarkers.
    • STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

      James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Anderson, John; Popert, Richard J; Sanders, Karen; Morgan, Rachel C; Stansfeld, J; et al. (2008-10)
    • Aetiology, diagnosis and management of urothelial tumours of the renal pelvis and ureter.

      Maddineni, Satish B; Clarke, Noel W; Sutherland, Douglas E; Jarrett, Thomas W; Department of Urology, Christie Hospital NHS Foundation Trust, Manchester, UK. (2008-11)
    • Survival from prostate cancer in England and Wales up to 2001.

      Clarke, Noel W; Department of Urological Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. noel.clark@srft.nhs.uk (2008-09-23)